# Vera Therapeutics

**Canonical:** https://apis.io/providers/vera-therapeutics/  
**Website:** https://veratx.com  
**APIs profiled:** 0

Vera Therapeutics is a clinical- and commercial-stage biopharmaceutical company based in Brisbane, California, developing treatments for serious immunological and inflammatory diseases of the kidney. Its lead program, atacicept (marketed as TRUTAKNA), is a dual BAFF/APRIL inhibitor for IgA nephropathy (IgAN). Surfaced as a portfolio company of GV and added to the API Evangelist network for enrichment, Vera Therapeutics publishes a corporate and patient-facing website (veratx.com) but exposes no public developer portal, API, SDKs, or machine-readable API surface. Sector: life-sciences.

## Kin Score — 9.0 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 9.0).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 21.1 |
| Access Clarity | 21.1 |

Regulatory layer — **Health**: 17.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Vera Therapeutics Domain Security** — TLSv1.3 · HSTS · DMARC

## Tags

Company, Life Sciences, Biopharmaceutical, Pharmaceuticals, Nephrology, Immunology, Healthcare

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/vera-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.